陈泽鹏;朱建红;伍俊妍;郑志华;
CHEN Zepeng;ZHU Jianhong;WU Junyan;ZHENG Zhihua;Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University;Guangdong Pharmaceutical Association;

• 1:中山大学孙逸仙纪念医院
• 2:广东省药学会

摘要(Abstract)：

目的运用循证药学的方法评价利拉鲁肽用于治疗超重或肥胖的临床证据,为超说明书用药循证评价提供参考。方法系统检索Pub Med、EMBASE、Cochrane Library、CNKI、万方数据库,国外药品说明书及MICROMEDEX~?循证数据库,由两名评价者独立的根据纳入排除标准筛选文章,评价文献质量,提取数据并分析。结果共纳入FDA与EMA药品说明书、循证数据库MICROMEDEX~?、5项国内外指南与6篇系统评价/Meta分析。利拉鲁肽与安慰剂相比可以显著降低肥胖患者的体重和BMI、提高体重减轻至少5%的患者比例。安全性方面利拉鲁肽由于不良反应而停止治疗的比率显著高于安慰剂,其中胃肠道不良反应发生率较高。结论利拉鲁肽用于治疗BMI>27 kg·m~(-2)合并至少一项肥胖并发症、或者BMI>30 kg·m~(-2)的单纯性肥胖的患者具有较好的疗效,但是需要注意患者胃肠道不良反应。
OBJECTIVE To evaluate the evidence of liraglutide in the treatment of overweight or obesity. METHODS Studies investigated the effect of liraglutide on overweight or obesity were searched using the following database:Pub Med,EMBASE,Cochrane Library,CNKI,Wanfang database,foreign drug instruction website and MICROMEXEX~? evidence-based database. Two reviewers selected articles based on inclusion and exclusion criteria,evaluated study quality,extracted and analyzed data independently.RESULTS The FDA and EMA package insert,data from MICROMEX~? and 6 systematic reviews/Meta analysis were included.Liraglutide significantly reduced the body weight and BMI of obese patients,and increased the proportion of patients with at least 5%weight loss compared with placebo. In terms of safety,the ratio of stopped treatment due to adverse reactions in liraglutide group was significantly higher than that of the placebo group,and the incidence of gastrointestinal adverse reactions was higher liraglutide group.CONCLUSION Liraglutide was effective in the treatment of patients with BMI > 27 kg·m~(-2) with at least one obesity complication,or simple obesity with BMI >30 kg·m~(-2),but attention should be paid to the gastrointestinal reactions.

关键词(KeyWords)： 利拉鲁肽;超说明书;有效性;安全性;循证评价
liraglutide;off-label;effective;safety;evidence-based evaluation

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈泽鹏;朱建红;伍俊妍;郑志华;
CHEN Zepeng;ZHU Jianhong;WU Junyan;ZHENG Zhihua;Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University;Guangdong Pharmaceutical Association;

Email:

DOI:

参考文献(References)：

• [1]关于印发《药品未注册用法专家共识》的通知[J]．今日药学，2010,20(4):1-3.
• [2]Müller T D,Clemmensen C,Finan B,et al. Anti-obesity therapy:from rainbow pills to polyagonists[J]. Pharmacol Rev,2018,70(4):712-746.
• [3]Bray G A,Heisel W E,Afshin A,et al. The science of obesity management:an endocrine society scientific statement[J]. Endocr Rev,2018,39(2):79-132.
• [4]广东省药学会．超药品说明书用药目录(2019年版)[J/OL]．今日药学[2019-11-13]. http://kns. cnki. net/kcms/detail/44. 1650.R.20190617.1523.044.html.
• [5]Shea B J,Grimshaw J M,Wells G A,et al. Development of AMSTAR:a measurement tool to assess the methodological quality of systematic reviews[J]. BMC Med Res Methodol,2007(7):10.
• [6]Novo Nordisk Inc. SAXENDA(R)subcutaneous injection solution,liraglutide(r DNA origin)subcutaneous injection solution[S].FDA,2014.
• [7]Novo Nordisk Limited. Saxenda 6 mg/ml solution for injection in pre-filled pen[S].EMA,2015.
• [8] IBM Watson Health. Micromedex(electronic version)[S].Greenwood Village,Colorado,USA. Available at:https://www. micromedexsolutions.com/(cited:24/10/2019).
• [9]中华人民共和国药典委员会．中华人民共和国药典临床用药须知[S]．北京:中国医药科技出版社，2015:631.
• [10]American Diabetes Association. Introduction:Standards of Medical Care in Diabetes[J]. Diabetes Care,2019,42(1):S1-S193.
• [11]Garber A J,Abrahamson M J,Barzilay J I,et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2018 executive summary[J]. Endocr Pract,2018,24(1):91-120.
• [12]Bray G A,Heisel W E,Afshin A,et al. The Science of Obesity Management:An Endocrine Society Scientific Statement[J]. Endocr Rev,2018,39(2):79-132.
• [13]Yumuk V,Tsigos C,Fried M,et al. European Guidelines for Obesity Management in Adults[J]. Obes Facts,2015,8(6):402-424.
• [14]Vilsb ll T,Christensen M,Junker A E,et al. Effects of glucagonlike peptide-1 receptor agonists on weight loss:systematic review and Meta-analyses of randomised controlled trials[J]. BMJ,2012(344):d7771.
• [15]Potts J E,Gray L J,Brady E M,et al. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes:A Systematic Review and Mixed Treatment Comparison Meta-Analysis[J]. PLo S One,2015,10(6):e0126769.
• [16]Zhang F,Tong Y,Su N,et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes:A systematic review and Meta-analysis of randomized controlled trials[J]. J Diabetes,2015,7(3):329-339.
• [17]Khera R,Murad M H,Chandar A K,et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events:A Systematic Review and Meta-analysis[J]. JAMA,2016,315(22):2424-2434.
• [18]Agency for Healthcare Research and Quality(US). Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults:An Updated Systematic Review for the U.S. Preventive Services Task Force[S].US,2018.
• [19]林尚，王德峰．利拉鲁肽对超重或肥胖2型糖尿病患者胰岛素抵抗影响的Meta分析[D]．邯郸:河北工程大学，2019.